Advertisement

Controversies in Empiric Therapy of Febrile Neutropenia

  • John R. Wingard
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

Antineoplastic chemotherapy regimens induced myelosuppression was quickly recognized as a major limitation to the full utility of cytotoxic drug regimens targeting cancer. Measures taken to mitigate harm from myelosuppression have led to a number of controversies over the years. The first controversy faced by clinicians was whether or not empiric antibiotic therapy for febrile neutropenia is appropriate. The concerns was that fever may be due to noninfectious causes, inappropriate antibiotic use might lead to emergence of resistance or superinfections by resistant organisms, the patient might experience toxicities (the antibiotics of those days had considerable toxicity), and the drugs were costly. This controversy was eventually resolved in favor of empiric antibiotics through a series of studies. Today, there are yet other controversies about empiric therapy of febrile neutropenia. These include questions as to whether there is an optimal antibiotic regimen, persistent concerns about resistance, questions as to what are the causes for fevers that have no apparent explanation, quandaries about the role for empiric antifungal therapy, and the unresolved issues as to why some patients become quite ill while ­others are less affected. Other controversies as to optimal management of venous catheters, etiology of neutropenic enterocolitis (typhlitis), the role for antimicrobial prophylaxis, and antibiotic resistance are addressed in other chapters and will not be covered here.

Keywords

Febrile neutropenia Empiric therapy Optimal antibiotic regimen Drug resistance Empiric antifungal therapy 

References

  1. 1.
    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infections diseases society of America. Clin Infect Dis. 2011;52(4):e56–93.PubMedCrossRefGoogle Scholar
  2. 2.
    Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008;6(2):122–74.PubMedGoogle Scholar
  3. 3.
    Link H, Böhme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever. Ann Hematol. 2003;82 Suppl 2:S105–17.PubMedCrossRefGoogle Scholar
  4. 4.
    Infectious Diseases Society of Taiwan; Hematology Society of Taiwan; Medical Foundation in Memory Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee’s Research Foundation for Pediatric Infectious Diseases and Vaccine. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005;38(6):455–7.Google Scholar
  5. 5.
    Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39 Suppl 1:S49–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7(5):338–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-­analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57(2):176–89.PubMedCrossRefGoogle Scholar
  8. 8.
    Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–214.PubMedCrossRefGoogle Scholar
  9. 9.
    Oude Nijhuis CS, Daenen SM, Vellenga E, et al. Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol. 2002;44(2):163–74.Google Scholar
  10. 10.
    Cockerill 3rd FR, Wilson JW, Vetter EA, et al. Optimal testing ­parameters for blood cultures. Clin Infect Dis. 2004;38(12):1724–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol. 2007;45(11):3546–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Spaargaren J, van Boven CP, Voorn GP. Effectiveness of resins in neutralizing antibiotic activities in bactec plus Aerobic/F culture medium. J Clin Microbiol. 1998;36(12):3731–3.PubMedGoogle Scholar
  13. 13.
    Flayhart D, Borek AP, Wakefield T, et al. Comparison of BACTEC PLUS blood culture media to BacT/Alert FA blood culture media for detection of bacterial pathogens in samples containing therapeutic levels of antibiotics. J Clin Microbiol. 2007;45(3):816–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Levin PD, Yinnon AM, Hersch M, Rudensky B. Impact of the resin blood culture medium on the treatment of critically ill patients. Crit Care Med. 1996;24(5):797–801.PubMedCrossRefGoogle Scholar
  15. 15.
    Woo PC, Wong SS, Lum PN, et al. Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet. 2001;357(9257):675–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ley BE, Linton CJ, Bennett DM, et al. Detection of bacteraemia in patients with fever and neutropenia using 16S rRNA gene amplification by polymerase chain reaction. Eur J Clin Microbiol Infect Dis. 1998;17(4):247–53.PubMedGoogle Scholar
  17. 17.
    Xu J, Moore JE, Millar BC, et al. Improved laboratory diagnosis of bacterial and fungal infections in patients with hematological malignancies using PCR and ribosomal RNA sequence analysis. Leuk Lymphoma. 2004;45(8):1637–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Ammann RA, Zucol F, Aebi C, et al. Real-time broad-range PCR versus blood culture. A prospective pilot study in pediatric cancer patients with fever and neutropenia. Support Care Cancer. 2007;15(6):637–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Woo PC, Lau SK, Teng JL, et al. Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect. 2008;14(10):908–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Dreier J, Störmer M, Kleesiek K. Real-time polymerase chain reaction in transfusion medicine: applications for detection of bacterial contamination in blood products. Transfus Med Rev. 2007;21(3):237–54.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamikami Y, Hashimoto A, Yamagata E, et al. Evaluation of PCR for detection of DNA specific for Aspergillus species in sera of patients with various forms of pulmonary aspergillosis. J Clin Microbiol. 1998;36(12):3619–23.Google Scholar
  22. 22.
    Hebart H, Löffler J, Reitze H, et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol. 2000;111(2):635–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Skladny H, Buchheidt D, Baust C, et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol. 1999;37(12):3865–71.PubMedGoogle Scholar
  24. 24.
    Morace G, Pagano L, Sanguinetti M, et al. PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol. 1999;37(6):1871–5.PubMedGoogle Scholar
  25. 25.
    Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal ­therapy by polymerase chain reaction – based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis. 2001;33:1621–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Lass-Flörl C, Aigner J, Gunsilius E, et al. Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol. 2001;113(1):180–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Jordanides NE, Allan EK, McLintock LA, et al. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplant. 2005;35(4):389–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205.PubMedCrossRefGoogle Scholar
  29. 29.
    Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive Aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190:641–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Arber C, Passweg JR, Fluckiger U, Pless M, Gregor M, Tichelli A, et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis. 2000;32(5):515–20.PubMedCrossRefGoogle Scholar
  33. 33.
    de Bel C, Gerritsen E, de Maaker G, Moolenaar A, Vossen J. C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation. Infection. 1991;19(2):92–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Engel A, Mack E, Kern P, Kern WV. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection. 1998;26(4):213–21.PubMedCrossRefGoogle Scholar
  35. 35.
    von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, Schmidt-Wolf IG, Marklein G, Schroeder S, Stuber F. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more ­reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23(7):539–44. Epub 2004 Jun 22.Google Scholar
  36. 36.
    Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–17.PubMedCrossRefGoogle Scholar
  37. 37.
    Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection. 2008;36(5):396–407.PubMedCrossRefGoogle Scholar
  38. 38.
    Persson L, Soderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U. Assessment of systemic inflammation markers to ­differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol. 2005;74(4):297–303.PubMedCrossRefGoogle Scholar
  39. 39.
    von Lilienfeld-Toal M, Schneider A, Orlopp K, Hahn-Ast C, Glasmacher A, Stuber F. Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer. 2006;14(12):1241–5.CrossRefGoogle Scholar
  40. 40.
    de Pauw BE. Between over- and undertreatment of invasive fungal disease. Clin Infect Dis. 2005;41(9):1251–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3):373–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Wingard JR. Empirical antifungal therapy in febrile neutropenic patients. Clin Infect Dis. 2004;39 Suppl 1:S38–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Wingard JR. New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Pract Res Clin Haematol. 2007;20(1):99–107.PubMedCrossRefGoogle Scholar
  45. 45.
    Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005;5:609–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Alexander BD, Pfeiffer RM. Contemporary tools for diagnosis and managment of invasive mycoses. Clin Infect Dis. 2006;43:S15–27.CrossRefGoogle Scholar
  47. 47.
    Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417–27.PubMedCrossRefGoogle Scholar
  48. 48.
    Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in ­neutropenic patients at high risk for invasive fungal infection: a ­prospective feasibility study. Clin Infect Dis. 2005;41:1242–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after Allo-SCT. Bone Marrow Transplant. 2009;43(7):553–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis. 2006;42(4):487–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet. 2001;358(9282):637–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet. 2001;358(9282):614–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Vekemans M, Robinson J, Georgala A, et al. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis. 2007;44(12):1593–601.PubMedCrossRefGoogle Scholar
  54. 54.
    Mølle I, Steffensen R, Thiel S, Peterslund NA. Chemotherapy-related infections in patients with multiple myeloma: associations with mannan-binding lectin genotypes. Eur J Haematol. 2006;77(1):19–26.PubMedCrossRefGoogle Scholar
  55. 55.
    Schlapbach LJ, Aebi C, Otth M, et al. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatr Blood Cancer. 2007;49(1):11–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Schlapbach LJ, Aebi C, Otth M, et al. Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J. 2007;26(11):989–94.PubMedCrossRefGoogle Scholar
  57. 57.
    Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood. 2002;99(10):3524–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Mølle I, Peterslund NA, Thiel S, Steffensen R. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006;38(8):555–60.PubMedCrossRefGoogle Scholar
  59. 59.
    Mullighan CG, Heatley SL, Danner S, et al. Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood. 2008;112(5):2120–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Mølle I, Ostergaard M, Melsvik D, Nyvold CG. Infectious ­complications after chemotherapy and stem cell transplantation in multiple myeloma: implications of Fc gamma receptor and myeloperoxidase promoter polymorphisms. Leuk Lymphoma. 2008;49(6):1116–22.PubMedCrossRefGoogle Scholar
  61. 61.
    Anaissie EJ, Zhao W, Wen Y et al. Deficiency of mannose-binding lectin is a risk factor for invasive pulmonary aspergillosis in patients with multiple myeloma: an analysis of 482 patients. Blood. 2008;112(11):249; Abstract 667.Google Scholar
  62. 62.
    Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359(17):1766–77.PubMedCrossRefGoogle Scholar
  63. 63.
    Woehrle T, Du W, Goetz A, et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine. 2008;41(3):322–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Wurfel MM, Gordon AC, Holden TD, et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med. 2008;178(7):710–20.PubMedCrossRefGoogle Scholar
  65. 65.
    Chien JW, Boeckh MJ, Hansen JA, Clark JG. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood. 2008;111(4):2462–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(12):1089–95.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of MedicineUniversity of FloridaGainesvilleUSA

Personalised recommendations